ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc (ARQT)

8.49
0.21
(2.54%)
Closed June 22 4:00PM
8.64
0.15
(1.77%)
After Hours: 6:55PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
8.64
Bid
8.25
Ask
8.80
Volume
8,671,634
8.21 Day's Range 8.66
1.76 52 Week Range 13.17
Market Cap
Previous Close
8.28
Open
8.31
Last Trade
12
@
8.7083
Last Trade Time
Financial Volume
$ 73,014,968
VWAP
8.42
Average Volume (3m)
2,889,030
Shares Outstanding
115,764,164
Dividend Yield
-
PE Ratio
-3.74
Earnings Per Share (EPS)
-2.26
Revenue
59.61M
Net Profit
-262.14M

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targe... Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arcutis Biotherapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARQT. The last closing price for Arcutis Biotherapeutics was $8.28. Over the last year, Arcutis Biotherapeutics shares have traded in a share price range of $ 1.76 to $ 13.17.

Arcutis Biotherapeutics currently has 115,764,164 shares outstanding. The market capitalization of Arcutis Biotherapeutics is $981.68 million. Arcutis Biotherapeutics has a price to earnings ratio (PE ratio) of -3.74.

ARQT Latest News

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment66.2% of participants treated with once-daily...

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.Β (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful...

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral sessionPreclinical data on ARQ-234, CD200R...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.61-6.594594594599.259.497.63524098748.25236329CS
4-0.53-5.779716466749.179.5356.9924895408.3334792CS
12-1.32-13.25301204829.9613.176.9928890309.20713101CS
265.92217.6470588242.7213.172.5141902657.63561561CS
52-0.7-7.494646680949.3413.171.7632910506.24086082CS
156-18.86-68.581818181827.527.881.7614715408.8579574CS
260-14.41-62.516268980523.0540.881.76106382310.04150463CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

ARQT Discussion

View Posts
52172 52172 1 month ago
Load the boat easy money
πŸ‘οΈ0
52172 52172 1 month ago
Buy opp!
πŸ‘οΈ0
52172 52172 1 month ago
ER coming on the 14th might get a bump then data in july
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
ARQT under $10
πŸ‘οΈ0
52172 52172 2 months ago
Oh yea!!!???
πŸ‘οΈ0
52172 52172 2 months ago
12 tomorrow!
πŸ‘οΈ0
Denisk Denisk 3 months ago
Headed much lower
πŸ‘οΈ0
Zorro Zorro 3 months ago
https://ih.advfn.com/stock-market/NASDAQ/arcutis-biotherapeutics-ARQT/stock-news/93458845/new-research-reveals-genomic-profile-of-seborrheic
πŸ‘οΈ0
52172 52172 4 months ago
Headed much higher
πŸ‘οΈ0
52172 52172 4 months ago
Some big buys ah
πŸ‘οΈ0
ANTADOG ANTADOG 5 months ago
4,38~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 5 months ago
4,31~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 5 months ago
4,19~~ ANT
πŸ‘οΈ0
ANTADOG ANTADOG 5 months ago
chart still intact after today, it's one of those stocks i really like and that's not only because of the recent fda approval, it's currently almost just between the 50 and 200ma, with that 50 ma curlin' up (2,44), i do hope u get more shares when the market allows it, i would add as well, but the best thing is: u got a starter, and we got an awesome chart, fyi ANT
πŸ‘οΈ0
Denisk Denisk 5 months ago
Only have 150 shares at average of $2.72 a share. Maybe will buy another 100 if price goes below $3.00
πŸ‘οΈ0
ANTADOG ANTADOG 5 months ago
one sell/profit takin' day after 3 buy days, and the way i see it, chart is still intact, ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
arqt chart upward trend intact, higher highs higher lows since 2 bucks ( start December), fyi ANT
πŸ‘οΈ0
ANTADOG ANTADOG 6 months ago
Arqt restless wants to visit 3,80's, imosho ANT
πŸ‘οΈ0
TommyBoyTrader9460 TommyBoyTrader9460 6 months ago
$ARQT
https://x.com/hannahadad8890/status/1740692333585367363?s=61
πŸ‘οΈ0
saigai saigai 6 months ago
hello blue skies
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
High of day $3.49, maybe we break $4.00 today
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
High of day $3.21, currently trading at $3.05
πŸ‘οΈ0
TraderX TraderX 6 months ago
Form 4 filed by CEO/President, if I'm reading this correctly.
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
Today's high was $2.93, I hope we can break $3 this week
πŸ‘οΈ0
saigai saigai 6 months ago
2.55 looking awfully smart
πŸ‘οΈ0
saigai saigai 6 months ago
zero downside risk from your entry
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
I entered $2.55 today
πŸ‘οΈ0
saigai saigai 6 months ago
arqt it aint over till the big lady sings. lets close strong
πŸ‘οΈ0
saigai saigai 6 months ago
3.19 i think i posted it in an earler post.. i have very little didcipline and more likely to chase early then wait for the inevitable retrace..
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
dipped to $2.48, I wonder if $2.44 will fill today.
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
What's your entry if you don't mind me asking
πŸ‘οΈ0
saigai saigai 6 months ago
bad entry great stock.. ill make smoney here
πŸ‘οΈ0
SmallCapValueInvestor SmallCapValueInvestor 6 months ago
Have a limit buy for $2.44, let's see
πŸ‘οΈ0
subslover subslover 6 months ago
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
ZORYVE foam represents a highly effective, safe, well-tolerated, once-daily steroid-free foam for use on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use
ZORYVE foam provides rapid disease clearance and significant reduction in itch, one of the most burdensome symptoms of seborrheic dermatitis
First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades
Seborrheic dermatitis affects more than 10 million people in the United States
Commercial product expected to be available by end of January
Management will host conference call on Monday, December 18 at 8:30 a.m. EST
WESTLAKE VILLAGE, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the new drug application (NDA) for ZORYVE (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE foam provides rapid disease clearance and significant reduction in itch, with nearly 80% of individuals achieving the primary efficacy endpoint of IGA Success and just over 50% of individuals reaching complete clearance at Week 8 in the STRATUM trial. ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

β€œWe know from dermatology clinicians and those living with seborrheic dermatitis that there has been a real struggle with disease clearance and treatment adherence due to lack of efficacy, difficulty treating certain body areas, inconvenient treatment regimens, and concerns about safety with long-term use,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis. β€œZORYVE foam is a once-daily, steroid-free topical treatment that can be used anywhere on the body, including hair-bearing areas, with no limitation on duration of use. We are proud to deliver meaningful innovation through this approval of ZORYVE foam, and to offer a new topical treatment that effectively clears and controls the disease and can simplify its management for the millions of adults and adolescents living with seborrheic dermatitis.”

Seborrheic dermatitis affects more than 10 million people in the United States, and is a common, chronic, and recurrent inflammatory skin disease that causes red patches covered with large, greasy, flaking yellow-gray scales, and persistent itch. In individuals with darker skin tones, inflamed areas may not appear red, but instead can appear pink, slightly purple, or lighter in color than the surrounding skin. It occurs most often in areas of the body with oil-producing (sebaceous) glands, including the scalp, face (especially on the nose, eyebrows, ears, and eyelids), upper chest, and back. Hair-bearing areas make applying topicals like creams, gels, and ointments difficult.

β€œIn the STRATUM trial, ZORYVE foam provided rapid disease clearance as early as Week 2 and significant itch relief in as little as 48 hours. In addition, almost 80% of patients achieved treatment success at Week 8. While multiple factors contribute to seborrheic dermatitis, inflammation and skin barrier dysfunction play key roles. ZORYVE has been shown to effectively reduce the signs of inflammation, redness, and scaling in patients with seborrheic dermatitis, and with its unique formulation, ZORYVE foam effectively delivers the drug without disrupting the skin barrier and has been shown to be safe and tolerable. ZORYVE foam is thus ideally formulated, having the potential to become the new standard of care for seborrheic dermatitis treatment,” said Andrew Blauvelt, MD, MBA, clinical investigator at Oregon Medical Research Center, and investigator on the STRATUM trial.

Beyond the appearance and irritation of physical symptoms, seborrheic dermatitis is associated with a decrease in quality of life and may negatively affect emotional well-being, self-esteem, and day-to-day life, including sleep and work. People with seborrheic dermatitis, and especially adolescents and school-age children, may suffer from social stigma, negative self-image, and low self-esteem associated with very visible skin diseases like seborrheic dermatitis.

β€œApproximately 10 million people in the United States have seborrheic dermatitis, but until today, there have been limited treatment options. We are thrilled with this FDA approval and are excited to bring to market a new, highly effective steroid-free topical formulation that can be used anywhere on the body,” said Frank Watanabe, president and CEO of Arcutis. β€œOur commercial team is ready and poised to launch ZORYVE foam very soon, and we are committed to ensuring affordable access to ZORYVE foam to those who may benefit from this novel treatment.”

Arcutis intends to make ZORYVE foam widely available via key wholesaler and dermatology pharmacy channels as a new treatment option by the end of January 2024. The Company is dedicated to responsible pricing and affordable access to therapy. The ZORYVE® Direct Program helps patients access their prescribed Arcutis medication. For patients with seborrheic dermatitis who have been prescribed ZORYVE, this patient support program helps patients navigate the payer process, assists patients with adherence, and includes the ZORYVE Direct Savings Card Program, which can help reduce out-of-pocket costs for eligible commercially insured patients.† Arcutis will also continue to offer the Arcutis CaresTM patient assistance program (PAP) that provides ZORYVE at no cost for financially eligible patients who are uninsured or underinsured.‑

Management will host a conference call on Monday, December 18 at 8:30 a.m. EST. A live webcast of the call and presentation material will be available on the β€œEvents” section of the Company's Investor website. An archived version of the webcast will be available on the Arcutis website after the call.

ZORYVE Foam Clinical Data
The approval is supported by positive results from Arcutis’ Phase 2 and pivotal Phase 3 trials in seborrheic dermatitis. The STudy of Roflumilast foam Applied Topically for the redUction of seborrheic derMatitis (STRATUM) and the Phase 2 (Trial 203) were parallel group, double-blind, vehicle-controlled studies evaluating the safety and efficacy of ZORYVE foam 0.3% in seborrheic dermatitis. Together the two studies enrolled 683 adults and adolescents ages 9 years and older.

The STRATUM study met its primary endpoint, with nearly 80% of ZORYVE foam treated individuals reaching Investigator Global Assessment (IGA) Success rate at Week 8 (79.5% ZORYVE foam vs 58.0% vehicle; P
πŸ‘οΈ0
Gunner54 Gunner54 6 months ago
Sell us on this company, links are appreciated
πŸ‘οΈ0
frans frans 6 months ago
FDA approval
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock